stockportfolio.pro
Stocks / KNSA vs ORKA
KNSA vs ORKA
Kiniksa Pharmaceuticals International, plc and Oruka Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Kiniksa Pharmaceuticals International, plc (KNSA) | Oruka Therapeutics, Inc. (ORKA) | |
|---|---|---|
| Market cap | $3.9B | $4.2B |
| Revenue (latest FY) | $677.56M | $0 |
| Net income (latest FY) | $59.01M | $-105.43M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | 8.7% | — |
| Return on equity | 10.4% | -22.5% |
| P/E ratio | 55.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KNSA — free Open ORKA — freeFrequently asked questions
Which is bigger, KNSA or ORKA?
Oruka Therapeutics, Inc. is larger by market capitalization — $4.2B versus $3.9B.
Which grows faster, KNSA or ORKA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.